First-in-class, cardioprotective drug with potential to transform treatment following myocardial infarction and stenting OSLO, Norway, May 22, 2023 /PRNewswire/ — Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.